• Bloomberg

  • SHARE

Chugai Pharmaceutical Co., the Japanese unit of Roche Holding AG, said first-quarter profit fell 50 percent from a year earlier because of a drop in sales of Tamiflu and Epogin, two of its three best-selling medicines.

Net income fell to ¥6.7 billion in the three months ended March 31, from ¥13.3 billion a year earlier, the Tokyo-based company said. Sales fell 27 percent to ¥66.2 billion, Chugai said.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW